APA (7th ed.) Citation

Namjoo, M., Ghafouri, H., Assareh, E., Aref, A. R., Mostafavi, E., Hamrahi Mohsen, A., . . . Asghari, S. M. (2023). A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities. Pharmaceuticals (14248247), 16(6), 906. https://doi.org/10.3390/ph16060906

Chicago Style (17th ed.) Citation

Namjoo, Mohadeseh, Hossein Ghafouri, Elham Assareh, Amir Reza Aref, Ebrahim Mostafavi, Ali Hamrahi Mohsen, Saeed Balalaie, Sylvain Broussy, and S. Mohsen Asghari. "A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities." Pharmaceuticals (14248247) 16, no. 6 (2023): 906. https://doi.org/10.3390/ph16060906.

MLA (9th ed.) Citation

Namjoo, Mohadeseh, et al. "A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities." Pharmaceuticals (14248247), vol. 16, no. 6, 2023, p. 906, https://doi.org/10.3390/ph16060906.